CMXHF
CSL Limited
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Buy
+50/100
Last price
127.68
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
127.68
Day high
128.50
Day low
128.50
Volume
100
Market cap
$61.27B
P/E (TTM)
—
52W range
63.84 – 148.36
Trailing performance
Returnvs SPY
1W
+0.25%
-1.7%
1M
+0.70%
-0.5%
3M
+47.81%
+43.3%
6M
+44.60%
+26.4%
YTD
+10.55%
-3.7%
1Y
-3.59%
-20.0%
3Y
-20.39%
-102.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CMXHF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
95.78K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 21, 26 | Price (Cameron Bruce) Independent Non-Executive Director |
— | 263 | — | Direct |
| Aug 21, 26 | Saroukos (Constantine) Independent Non-Executive Director |
— | 512 | — | Direct |
| Aug 21, 26 | Watkins (Alison Mary) Independent Non-Executive Director |
BUY | 213 | $33.50K | Direct |
| Aug 21, 26 | Cuthbertson (Robert Andrew) Independent Non-Executive Director |
— | 183 | — | Direct |
| Aug 21, 26 | Hewson (Carolyn Judith) Independent Non-Executive Director |
— | 244 | — | Direct |
| Aug 21, 26 | Lewis (Samantha Louise) Independent Non-Executive Director |
— | 152 | — | Direct |
| Aug 21, 26 | McNamee (Brian Anthony) Independent Non-Executive Director |
— | 433 | — | Direct |
| Jun 1, 26 | Hewson (Carolyn Judith) Independent Non-Executive Director |
BUY | 1.04K | $71.08K | Direct |
| May 26, 26 | Naylor (Gordon) Director (Non-Executive) |
BUY | 1.10K | $77.26K | Direct |
| May 15, 26 | Watkins (Alison Mary) Independent Non-Executive Director |
BUY | 2.54K | $179.13K | Direct |
| Feb 17, 26 | Watkins (Alison Mary) Independent Non-Executive Director |
— | 214 | — | Direct |
| Feb 17, 26 | Cuthbertson (Robert Andrew) Independent Non-Executive Director |
— | 183 | — | Direct |
| Feb 17, 26 | Hewson (Carolyn Judith) Independent Non-Executive Director |
— | 244 | — | Direct |
| Feb 17, 26 | Lewis (Samantha Louise) Independent Non-Executive Director |
— | 153 | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Clark (Megan Elizabeth) |
Independent Non-Executive Director | 5.72K | Purchase |
Daniels (Brian M.D.) |
Non-Independent Executive Director | 3.40K | Purchase |
Hewson (Carolyn Judith) |
Independent Non-Executive Director | 4.13K | Purchase |
Lewis (Samantha Louise) |
Independent Non-Executive Director | 2.52K | Purchase |
Linton (Joy) |
Chief Financial Officer | 15.10K | Other |
McKenzie (Paul F) |
Chief Executive Officer | 31.05K | Exercise |
McNamee (Brian Anthony) |
Independent Non-Executive Director | 30.56K | Purchase |
Naylor (Gordon) |
Director (Non-Executive) | 40.82K | Purchase |
Price (Cameron Bruce) |
Independent Non-Executive Director | 3.56K | Purchase |
Schmeltz (Andy) |
Other Executive | 5.07K | Other |
Fundamentals
Market cap$61.27B
Enterprise value$72.04B
Revenue (TTM)$15.80B
Gross profit$8.07B
EBITDA$5.08B
Net income$-2.58B
EPS (TTM)$-5.35
Free cash flow$1.89B
Total cash$1.51B
Total debt$10.90B
Book value / share$30.90
Shares outstanding479.88M
Float478.53M
Short % of float—
Dividend yield2.22%
Beta (5Y)0.08
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book4.13
EV / revenue4.56
EV / EBITDA14.19
Gross margin51.12%
Operating margin21.49%
Profit margin-16.33%
Return on equity-15.83%
Return on assets7.26%
Debt / equity66.82
Current ratio2.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $15.70B | $15.43B | $14.69B | $13.17B | — | +1.7% |
| Operating revenue | $15.70B | $15.43B | $14.69B | $13.17B | — | +1.7% |
| Cost of revenue | $7.72B | $7.48B | $7.13B | $6.47B | — | +3.2% |
| Gross profit | $7.98B | $7.95B | $7.56B | $6.71B | — | +0.3% |
| Research & development | $1.22B | $1.36B | $1.43B | $1.24B | — | -10.0% |
| Selling, general & admin | $2.61B | $2.62B | $2.43B | $2.54B | — | -0.2% |
| Total operating expense | $4.88B | $4.99B | $4.80B | $4.61B | — | -2.3% |
| Operating income | $3.10B | $2.96B | $2.76B | $2.10B | — | +4.8% |
| Net interest income | -$405.00M | -$410.00M | -$437.00M | -$406.00M | — | +1.2% |
| Pre-tax income | -$4.09B | $3.72B | $3.38B | $2.66B | — | -209.7% |
| Tax provision | -$1.10B | $588.00M | $661.00M | $419.00M | — | -287.2% |
| Net income | -$2.58B | $3.00B | $2.64B | $2.19B | — | -185.9% |
| Net income to common | -$2.58B | $3.00B | $2.64B | $2.19B | — | -185.9% |
| Basic EPS | — | 6.20 | 5.47 | 4.55 | 4.81 | — |
| Diluted EPS | — | 6.17 | 5.45 | 4.53 | 4.80 | — |
| EBIT | -$3.71B | $4.12B | $3.79B | $3.07B | — | -190.0% |
| EBITDA | -$2.66B | $5.13B | $4.73B | $3.90B | — | -151.9% |
| Basic shares | — | 484.04M | 483.01M | 482.17M | 468.75M | — |
| Diluted shares | — | 486.55M | 484.77M | 484.33M | 469.73M | — |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.51B | $2.16B | $1.66B | $1.55B | -29.9% |
| Cash & short-term investments | $1.51B | $2.16B | $1.66B | $1.55B | -29.9% |
| Accounts receivable | $2.75B | $2.28B | $2.09B | $1.42B | +20.6% |
| Inventory | $6.63B | $6.47B | $5.96B | $5.47B | +2.5% |
| Total current assets | $11.83B | $11.85B | $10.77B | $9.26B | -0.2% |
| Property, plant & equipment | $8.21B | $9.80B | $9.66B | $9.35B | -16.2% |
| Goodwill & intangibles | $10.96B | $16.18B | $16.35B | $16.45B | -32.3% |
| Total assets | $33.65B | $39.40B | $38.02B | $36.23B | -14.6% |
| Total current liabilities | $5.35B | $4.81B | $4.95B | $4.61B | +11.2% |
| Current debt | $1.00B | $695.00M | $848.00M | $964.00M | +44.3% |
| Long-term debt | $8.38B | $9.14B | $9.67B | $9.56B | -8.3% |
| Total debt | $10.90B | $11.50B | $12.18B | $12.23B | -5.2% |
| Total liabilities | $17.34B | $18.00B | $18.62B | $18.41B | -3.7% |
| Retained earnings | $13.70B | $17.74B | $16.01B | $14.62B | -22.8% |
| Shareholder equity | $14.80B | $19.34B | $17.36B | $15.79B | -23.5% |
| Working capital | $6.48B | $7.04B | $5.82B | $4.65B | -7.9% |
| Net tangible assets | $3.83B | $3.15B | $1.02B | -$660.00M | +21.7% |
| Shares issued | 478.91M | 484.21M | 483.25M | 482.37M | -1.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$1.28B | -$1.02B | -$1.26B | -$1.69B | -25.9% |
| Investing cash flow | -$1.27B | -$850.00M | -$1.26B | -$11.84B | -49.5% |
| Share buybacks | -$724.00M | — | — | — | — |
| Dividends paid | -$1.57B | -$1.43B | -$1.27B | -$1.24B | -9.3% |
| Financing cash flow | -$2.83B | -$2.24B | -$1.28B | $456.00M | -26.2% |
| Free cash flow | $2.23B | $2.54B | $1.51B | $909.00M | -12.3% |
| End cash position | $1.51B | $2.16B | $1.64B | $1.51B | -29.9% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | YoY |
|---|---|---|
| Cash & equivalents | $1.51B | |
| Cash & short-term investments | $1.51B | |
| Accounts receivable | $2.75B | |
| Inventory | $6.63B | |
| Total current assets | $11.83B | |
| Property, plant & equipment | $8.21B | |
| Goodwill & intangibles | $10.96B | |
| Total assets | $33.65B | |
| Total current liabilities | $5.35B | |
| Current debt | $1.00B | |
| Long-term debt | $8.38B | |
| Total debt | $10.90B | |
| Total liabilities | $17.34B | |
| Retained earnings | $13.70B | |
| Shareholder equity | $14.80B | |
| Working capital | $6.48B | |
| Net tangible assets | $3.83B | |
| Shares issued | 478.91M |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $15.76B | -0.2% |
| Next year | — | — | $16.32B | +3.6% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.02%
Held by institutions38.27%
Institutions holding395
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
127.11
+0.45% from price
SMA 20
125.87
+1.44% from price
SMA 50
114.04
+11.96% from price
SMA 100
95.35
+33.90% from price
SMA 200
100.21
+27.41% from price
EMA 12
126.61
+0.84% from price
EMA 26
123.12
+3.70% from price
EMA 50
115.32
+10.72% from price
RSI (14)
62.0
Neutral
MACD (12,26,9)
3.49
Hist -0.74
ATR (14)
2.28
1.78% of price
Realised vol 30D
36.1%
Annualised
Bollinger upper
130.97
20, 2σ
Bollinger lower
120.77
20, 2σ
50 / 200 cross
Golden
114.04 vs 100.21
Trend bias
Above 200
+27.41%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.35
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
36.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.1%
Peak to trough
Max drawdown 5Y
-71.4%
Peak to trough
ATR 14
2.28
1.78% of price
Beta (reported)
0.08
5Y monthly, from filing
Dividends & splits
Forward rate$2.83 / yr
Forward yield2.22%
5-year avg yield1.44%
Payout ratio45.11%
Ex-dividend dateSep 9, 2026
Next pay dateApr 4, 2014
Last split—
Split date—
Headlines
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
Zacks · 22h ago
CSL (ASX:CSL) Could Be 15% Undervalued After Its $355 Million Alentis Deal
Simply Wall St. · 1d ago
CSL to pay up to $1.6 bln to develop rare disease drug; shares rise
Investing.com · 2d ago
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
PR Newswire · 3d ago
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
CNW Group · 3d ago
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
PR Newswire · 3d ago
CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign
PR Newswire · 8d ago
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors
Business Wire · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.